Zivo Bioscience Inc (ZIVO)

[Amigo Mike]

Weazel,

My sentiments exactly.

Once this company has some measure of success, I suspect the "tune" will be vastly different and the proclamations of doom and selling when offered won't happen either.

Proves my point about unreasoned thought. Does nobody any good. Step back and look at what is happening .... the framework is there. The finish line in sight for 1 or 2 license opportunities. The bioactive needs to continue proving positive ....... and then we'll see.

It isn't spreading lies. It isn't running a scam.

The collaboration with Zoetis .... ZOETIS IS IN CONTROL and HEPI can't say a damn thing that Zoetis doesn't allow them to say. Quite frankly I still marvel at how HEPI was even allowed to offer their name. All this testing for bovine is what ZOETIS REQUIRES in order to determine whether or not to license the bioactive. Dunno who the partner is driving requests on canine, but either Zoetis or another potential partner is driving what they wanna see for those tests as well. There is no way that HEPI is doing these tests for fun. It is expensive and time consuming ..... but ultimately, that is what these major players require.

I'm sure a tiny company like HEPI is bursting at the seams to speak more freely, but if it isn't Zoetis, it would be the FDA, FTC and any other governing body watching intently on any "claims" made.

BOttomline, the summary from the March 31 letter to shareholders sums it up pretty well ......

Summary

Other challenges surely await us. Communicating the complexities of the experiments and what they mean is equally difficult without revealing confidential information or placing potential patent claims in jeopardy. Over the last two years, Health Enhancement Products has firmly repositioned itself as a credible biotech R&D entity. The scale and complexity of the science demands a careful, measured approach, significant funding, and involves well-known researchers at the top of their game and in high demand. Schedules tend to stretch out as we accommodate the time demands of academic researchers and the availability of contract research organizations to handle our research requests.

Our target customers and potential partners are sophisticated, well-regarded scientists from global pharmaceutical companies and food ingredient manufacturers. They demand a level of documentation and validation consistent with the work product of other leading biotech companies -- a standard that HEPI strives to match in every test and experiment it undertakes, in every report or presentation it creates.

The team has worked diligently over the past year to transform perception of the Company from that of an interesting backwater stock play into a biotech contender with exciting prospects in the near term. Wherever the research may lead, and whatever prospects face the Company, opportunity favors the well-prepared.

Amigo Mike